A detailed history of Vanguard Group Inc transactions in Prelude Therapeutics Inc stock. As of the latest transaction made, Vanguard Group Inc holds 1,021,770 shares of PRLD stock, worth $1.07 Million. This represents 0.0% of its overall portfolio holdings.

Number of Shares
1,021,770
Previous 1,010,565 1.11%
Holding current value
$1.07 Million
Previous $3.85 Million 45.06%
% of portfolio
0.0%
Previous 0.0%

Shares

13 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2024

Nov 13, 2024

BUY
$2.07 - $6.37 $23,194 - $71,375
11,205 Added 1.11%
1,021,770 $2.12 Million
Q2 2024

Aug 13, 2024

SELL
$3.32 - $5.63 $21,360 - $36,223
-6,434 Reduced 0.63%
1,010,565 $3.85 Million
Q1 2024

May 10, 2024

BUY
$2.68 - $4.84 $27,183 - $49,092
10,143 Added 1.01%
1,016,999 $4.82 Million
Q4 2023

Feb 14, 2024

BUY
$1.69 - $4.37 $56,192 - $145,302
33,250 Added 3.42%
1,006,856 $4.3 Million
Q3 2023

Nov 14, 2023

BUY
$2.74 - $4.79 $56,630 - $98,999
20,668 Added 2.17%
973,606 $3.01 Million
Q2 2023

Aug 14, 2023

BUY
$4.45 - $8.12 $164,311 - $299,822
36,924 Added 4.03%
952,938 $4.29 Million
Q1 2023

May 15, 2023

BUY
$4.58 - $7.34 $76,486 - $122,578
16,700 Added 1.86%
916,014 $5.22 Million
Q4 2022

Feb 10, 2023

BUY
$4.61 - $8.5 $1,240 - $2,286
269 Added 0.03%
899,314 $5.43 Million
Q2 2022

Aug 12, 2022

BUY
$4.0 - $7.55 $394,188 - $744,029
98,547 Added 12.31%
899,045 $4.69 Million
Q1 2022

May 13, 2022

BUY
$6.9 - $13.22 $200,500 - $384,146
29,058 Added 3.77%
800,498 $5.52 Million
Q4 2021

Feb 14, 2022

SELL
$11.89 - $31.74 $4.34 Million - $11.6 Million
-365,282 Reduced 32.13%
771,440 $9.6 Million
Q3 2021

Nov 12, 2021

BUY
$25.78 - $38.65 $275,201 - $412,588
10,675 Added 0.95%
1,136,722 $35.5 Million
Q2 2021

Aug 13, 2021

BUY
$28.63 - $44.3 $32.2 Million - $49.9 Million
1,126,047 New
1,126,047 $32.2 Million

Others Institutions Holding PRLD

About Prelude Therapeutics Inc


  • Ticker PRLD
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 36,369,200
  • Market Cap $38.2M
  • Description
  • Prelude Therapeutics Incorporated, a clinical-stage precision oncology company, focuses on the discovery and development of novel precision cancer medicines to underserved patients. It is developing PRT543 that is in Phase 1 clinical trials in select solid tumors and myeloid malignancies; and PRT811, which is in Phase 1 clinical trials in solid ...
More about PRLD
Track This Portfolio

Track Vanguard Group Inc Portfolio

Follow Vanguard Group Inc and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Vanguard Group Inc, based on Form 13F filings with the SEC.

News

Stay updated on Vanguard Group Inc with notifications on news.